skip to Main Content

Pioneering a new approach to enable biological discovery.

IPI is a nonprofit research hybrid, blending an academic mindset with industrial scalability.
We are dedicated to sharing our antibodies and data broadly and openly.

Collaboration is our solution.

We are powering biological discovery and therapeutic development by enabling scientists with our expertise and tools.

Protein Science Expertise

Our Harvard-based scientists collaboratively take on complex projects in the areas most in need of transformative antibodies and other proteins.

Antibody Platform

We can achieve unprecedented scale with a platform and technologies based on high-quality protein and antibody design, expression and production.

The benefits of working with us.

Customizable Antibodies

Diverse and designed to work in your assays.

New Discoveries

You understand the biology. We know the proteins.

Unique Business Model

Balancing open science with intellectual property protection.

Expert Insights

Deep knowledge of protein structure and engineering.

Want to work with us?

Get access, move faster and stay ahead.

Academic collaboration

IPI’s Rob Meijers, Ph.D., talks about his initiative in the neuroscience community to freely distribute synthetic antibodies to intractable targets for validation in researchers assays.

Research sponsorship

IPI’s Stephen Fuchs, Ph.D., talks about his success with biotech and foundations in balancing customization and licensing models with open science.

Shwachman-Diamond syndrome research

IPI postdoctoral researcher James Bowman, Ph.D., joined researchers at Boston Children’s Hospital and Dana-Farber Cancer Institute to unravel the genetics of a rare and elusive disease. Not only did the Institute’s protein expertise help illuminate a new route for therapy, it also provided answers to Bowman’s own cousin — who happened to be born with the disease.

Get in touch today.
Back To Top